X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (306) 306
hematology (214) 214
male (206) 206
female (198) 198
oncology (195) 195
index medicus (191) 191
middle aged (182) 182
adult (171) 171
aged (142) 142
antineoplastic combined chemotherapy protocols - therapeutic use (103) 103
treatment outcome (95) 95
chemotherapy (87) 87
rituximab (80) 80
prognosis (72) 72
disease-free survival (71) 71
lymphomas (70) 70
non-hodgkins-lymphoma (63) 63
aged, 80 and over (60) 60
retrospective studies (59) 59
neoplasm staging (51) 51
antineoplastic agents - therapeutic use (50) 50
cancer (49) 49
lymphoma (48) 48
therapy (48) 48
adolescent (47) 47
recurrence (46) 46
remission induction (46) 46
survival analysis (46) 46
classification (44) 44
lymphoma, non-hodgkin - drug therapy (41) 41
cyclophosphamide - administration & dosage (40) 40
combined modality therapy (39) 39
hemic and lymphatic diseases (39) 39
antineoplastic combined chemotherapy protocols - administration & dosage (38) 38
follicular lymphoma (38) 38
hematology, oncology and palliative medicine (36) 36
phase-ii (36) 36
vincristine - administration & dosage (36) 36
care and treatment (34) 34
disease (34) 34
young adult (33) 33
follow-up studies (32) 32
prednisone - administration & dosage (32) 32
brentuximab vedotin (31) 31
doxorubicin - administration & dosage (31) 31
survival (31) 31
b-cell lymphoma (27) 27
vidarabine - analogs & derivatives (27) 27
fludarabine (26) 26
lymphoma, large b-cell, diffuse - drug therapy (26) 26
transplantation (26) 26
patients (25) 25
trial (25) 25
antibodies, monoclonal - therapeutic use (24) 24
cyclophosphamide (24) 24
immune system diseases (24) 24
survival rate (24) 24
analysis (23) 23
abridged index medicus (22) 22
antineoplastic agents (22) 22
bleomycin - administration & dosage (22) 22
cancer research (22) 22
hodgkin disease - drug therapy (22) 22
non-hodgkin's lymphomas (22) 22
phase-ii trial (22) 22
time factors (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
drug administration schedule (21) 21
positron-emission-tomography (21) 21
response criteria (21) 21
salvage therapy (21) 21
antineoplastic agents - adverse effects (20) 20
high-dose chemotherapy (20) 20
hodgkin's disease (20) 20
malignant-lymphoma (20) 20
radiotherapy (20) 20
t cells (20) 20
chronic lymphocytic-leukemia (19) 19
stem cell transplantation (19) 19
antibodies, monoclonal, murine-derived (18) 18
follow-up (18) 18
hematopoietic stem cell transplantation (18) 18
hodgkin disease - pathology (18) 18
italy (18) 18
lymphoma, large b-cell, diffuse - pathology (18) 18
macop-b (18) 18
radioimmunotherapy (18) 18
transplantation, autologous (18) 18
vidarabine - administration & dosage (18) 18
antibodies, monoclonal, murine-derived - administration & dosage (17) 17
antineoplastic combined chemotherapy protocols (17) 17
etoposide - administration & dosage (17) 17
gemcitabine (17) 17
lymphoma, large b-cell, diffuse - mortality (17) 17
lymphoma, non-hodgkin - mortality (17) 17
lymphoma, non-hodgkin - therapy (17) 17
prednisone (17) 17
research (17) 17
antibodies, monoclonal - administration & dosage (16) 16
chop (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hematological Oncology, ISSN 0278-0232, 04/2019, Volume 37, Issue 2, pp. 202 - 204
Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case... 
Sézary syndrome | experimental drugs | prolonged disease control | Sezary syndrome | ONCOLOGY | MYCOSIS-FUNGOIDES | UPDATE | HEMATOLOGY | Gemcitabine | Medical innovations | Stem cells | Case reports | Stem cell transplantation | Transplantation | Disease control | Immunosuppressive agents
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 10/2018, Volume 16, Issue 10, pp. 1263 - 1265
Journal Article
BLOOD CANCER JOURNAL, ISSN 2044-5385, 05/2019, Volume 9, Issue 6, pp. 48 - 10
Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or... 
OF-ORIGIN | MOLECULAR CLASSIFICATION | PROGNOSTIC IMPACT | PARAFFIN-EMBEDDED TISSUE | ONCOLOGY | R-CHOP | GENE-EXPRESSION | GERMINAL CENTER | OPEN-LABEL | HEMATOLOGY | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Gene expression | Medical prognosis | Lymphomas
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1528 - 1528
Abstract Introduction: There remains a high unmet medical need for new therapies for patients with relapsed or refractory (R-R) B-cell non-Hodgkin's lymphoma... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1283 - 1294
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 10/2018, Volume 16, Issue 10, pp. 1263 - 1266
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3088 - 3088
Abstract active and well tolerated single agent in the treatment of heavily pretreated Hodgkin lymphoma patients. In this pilot phase II study patients with... 
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 12/2015, Volume 13, Issue 12, pp. 1291 - 1293
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012, Volume 2012, pp. 426 - 432
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1013 - 1022
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10094, pp. 555 - 566
Journal Article
[Rinshō ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 10/2014, Volume 55, Issue 10, pp. 1937 - 1940
Journal Article
Journal Article